![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
National Institute of Mental Health (NIMH) |
Information provided by: | National Institute of Mental Health (NIMH) |
ClinicalTrials.gov Identifier: | NCT00429273 |
This study will evaluate the effectiveness of a single drug versus a combination of drugs in treating attention deficit hyperactivity disorder in children.
Condition | Intervention | Phase |
Attention Deficit Disorder With Hyperactivity |
Drug: Methylphenidate (MPH) Drug: Guanfacine Drug: Combined methylphenidate and guanfacine |
Phase IV |
MedlinePlus related topics: | Attention Deficit Hyperactivity Disorder |
ChemIDplus related topics: | Methylphenidate hydrochloride Methylphenidate Guanfacine Guanfacine hydrochloride Dexmethylphenidate Dexmethylphenidate hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years |
Estimated Enrollment: | 180 |
Study Start Date: | January 2007 |
Estimated Study Completion Date: | July 2011 |
Estimated Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
Group 1: Active Comparator
Participants will take guanfacine only
|
Drug: Guanfacine
Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
|
Group 2: Active Comparator
Participants will take methylphenidate only
|
Drug: Methylphenidate (MPH)
Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
|
Group 3: Experimental
Participants will take guanfacine and methylphenidate combined
|
Drug: Combined methylphenidate and guanfacine
Dosing as described for guanfacine and methylphenidate
|
Attention deficit hyperactivity disorder (ADHD) is one of the most common childhood mental disorders. Children with ADHD have impaired functioning in multiple settings, including home and school. They also have difficulty relating with peers. If left untreated, the disorder may cause adverse effects that can last into adolescence and adulthood. Stimulant medications, such as methylphenidate, are effective in reducing ADHD symptoms on a short-term basis. However, few long-term benefits in academic or general functioning from current ADHD therapies have been demonstrated. Focalin XR is a stimulant medication that is FDA-approved for treating ADHD. Guanfacine is another medication that is currently approved for the treatment of hypertension, but has long been used for treating ADHD. This study will determine the effectiveness of a combination of Focalin XR and guanfacine in enhancing cognitive functioning and improving the long-term benefit of ADHD treatment.
Participants in this study will be randomly assigned to one of three treatment regimens: Focalin XR and placebo; guanfacine and placebo; or Focalin XR and guanfacine. The study will be conducted in two phases: an 8-week double-blind treatment phase and a 12-month open-label treatment phase. In Phase I, one third of participants will receive placebo for the initial 4 weeks, followed by Focalin XR alone for the remaining 4 weeks. All other participants will receive their assigned medications for the full 8 weeks. All participants will attend two study visits prior to beginning treatment and one study visit per week throughout Phase I. At the end of Phase I, treatment assignments will be unblinded. Participants who experienced adequate improvement with their assigned treatment will then continue in Phase II on the same medication(s) for an additional 12 months. Participants will attend study visits once per month until the end of the study. Study visits will include self-report measures, clinical assessments, and cognitive testing. Participants will also undergo four electroencephalography (EEG) tests and two fMRI scans over the course of the study. All Phase II participants will receive a follow-up telephone call 1 month after the final study visit.
Ages Eligible for Study: | 7 Years to 14 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Joni Zuckerbrow-Miller | 310-295-7667 | jzuckerbrow@mednet.ucla.edu |
United States, California | |||||
University of California Los Angeles | Recruiting | ||||
Los Angeles, California, United States, 90095 | |||||
Contact: Fiona Whelan, M.S. 310-825-7874 fwhelan@mednet.ucla.edu | |||||
Principal Investigator: James T. McCracken, MD | |||||
Sub-Investigator: James J. McGough, MD | |||||
Sub-Investigator: Robert Bilder, Ph.D. |
Principal Investigator: | James T. McCracken, MD | University of California, Los Angeles |
Study Director: | James J. McGough, MD | University of California, Los Angeles |
Responsible Party: | UCLA ( James McCracken, MD ) |
Study ID Numbers: | P50 MH77248, DDTR B2-NDH |
First Received: | January 29, 2007 |
Last Updated: | March 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00429273 |
Health Authority: | United States: Federal Government |
|
|
|
|
|
|
![]() |